Octapharma issues recall of one lot of its immune globulin Octagam

Octagam voluntary recall.

Switzerland’s Octapharma AG has issued an urgent, voluntary recall of one lot of its Octagam immune globulin used intravenously after several reports of allergic type skin reactions.

The lot Octagam Immune Globulin Intravenous (Human) 5% being recalled is K551A8441 and was manufactured at the company’s facility in Vienna, Austria. The plant received FDA approval to produce the drug a little over a year ago.

No other lots of Octagam are affected by the recall, the company said in a posting on the FDA website.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Octagam is used to treat primary humoral immunodeficiencies, such as congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and other severe combined immunodeficiencies.

No serious injuries from the products have been reported.

In October, Octapharma shelled out about $91 million to gain exclusive global license to certain intellectual property behind Glycotope’s recombinant technology as well as a minority stake in the German biotech.

-see the FDA posting

Related Article:
Octapharma buys into Glycotope with an €80M cash deal


Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.